Lv2
170 积分 2025-12-31 加入
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer
2天前
已完结
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression
4个月前
已完结
Understanding XPO1 Target Networks Using Systems Biology and Mathematical Modeling
7个月前
已完结
皖公网安备34019202002308
